Feature | October 26, 2011| Dave Fornell

FDA Panel Recommends Approval of Transcatheter Aortic Valve

Top experts, organizations push for clearance of the Edwards’ Sapien

The Sapien will likely become the first transcatheter aortic valve cleared for use in the United States. However, its use will likely be limited to a small number of specialized centers.

The Edwards Sapien transcatheter aortic valve is pending FDA clearnance. The valve can be delivered both transfemorally (pictured here) or transapically in a hybrid OR.

In a closely watched move – viewed as a big step toward a paradigm shift in how heart valves are repaired in the United States – a U.S. Food and Drug Administration (FDA) advisory panel in July recommended approval of the Edwards Lifesciences Sapien transcatheter heart valve.


The FDA Circulatory System Devices Panel recommended the valve specifically for the treatment of patients too sick to undergo the standard therapy of surgical valve replacement. While the FDA is not required to follow the approval recommendation from the committee, the agency takes the advice into consideration when rendering its final decisions. The FDA will likely consider final market clearance of the Sapien later this year.


The valve is delivered using minimally invasive, percutaneous cath lab delivery techniques. It is designed for treatment of patients with severe symptomatic native aortic valve stenosis who are unable to undergo valve replacement surgery. However, it is widely anticipated that transcatheter aortic valve implantation (TAVI) in the future will replace the current standard of open-heart surgery to repair or replace heart valves.


“The FDA panel’s recommendation further reinforces the value of TAVI for inoperable patients,” said Christopher J. White, M.D., FSCAI, SCAI president, chairman of the department of cardiology and director of the Ochsner Heart and Vascular Institute in New Orleans. “For more than 30 years, advances in interventional cardiology have helped improve survival for patients with heart disease. TAVI is an important advancement…”


The Sapien valve is an investigational device in the United States and not yet available commercially. It received CE mark approval for European commercial sale in late 2007. Edwards submitted an FDA pre-market approval (PMA) application in the fall of 2010, based on data from the inoperable cohort of the PARTNER trial. This cohort compared the outcomes of 358 patients after treatment with either standard medical therapy (usually balloon aortic valvuloplasty) or the Sapien valve delivered transfemorally. The results, released at Transcatheter Cardiovascular Therapeutics (TCT) 2010 last fall, were so overwhelmingly positive for the valve that top cardiologists questioned the ethics of continuing to randomize patients to ineffective valvuloplasty or medical therapy treatments.


“We are pleased with the panel’s strong recommendation for approval, and would like to thank them for their comprehensive and thoughtful review of the data presented from the PARTNER trial,” said Michael A. Mussallem, Edwards’ chairman and CEO. “This represents another important step on the path to what we hope will lead to FDA approval of Sapien.”


The Success of the PARTNER Trial
Speaking in support of the device at the panel meeting were American College of Cardiology (ACC) President David R. Holmes Jr., M.D., FACC; Michael J. Mack, M.D., FACC, president of The Society of Thoracic Surgeons (STS), and Augusto Pichard, M.D., FACC, FSCAI, speaking for the Society for Cardiovascular Angiography and Interventions (SCAI). All of them urged the FDA to approve this recommendation based on the results of the PARTNER cohort B trial. (1)


The study found lower rates of mortality among patients who received TAVI (30.7 percent vs. 50.7 percent, p<0.001) and lower rates of a composite endpoint of death from any cause or repeat hospitalization (42.5 percent vs. 71.6 percent, p<0.001). TAVI was associated with a significant reduction in symptoms.


However, TAVI was also associated with more neurological events, including strokes, major vascular complications and major bleeding events as compared to the standard therapy group. Part of this was attributed to the operator learning curve in mastering the techniques required for the new therapy. The trial was also performed without the use of aortic embolic protection devices, which are now being developed in hopes of reducing neurological and stroke events.


SCAI issued a statement saying the risk of stroke and vascular complications is always of concern, but the risk is offset by a dramatic benefit in survival. “For patients unable to receive surgery, the survival benefit of TAVI far outweighs the risk of complications and far exceeds the benefit of medical therapy,” the statement read.


“Patients with severe aortic stenosis have very few options and they need treatments like TAVI or they could die from their disease,” said Pichard, who is director of the cardiac catheterization lab at Washington Hospital Center and professor of medicine at Georgetown University. “The PARTNER B trial demonstrates TAVI significantly improves symptoms compared to standard treatments for patients who cannot receive surgery. We urge the FDA to approve this device and allow patients a treatment option that improves quality of life and extends lives.”


Preparing for a New Era
If  TAVI is approved by the FDA and becomes available for use in the United States, SCAI believes it will be essential for cardiovascular societies to work together to define program accreditation criteria and develop rigorous training program standards to train physicians. SCAI also said there is a need to establish a nationwide registry to monitor patient complications from these procedures and develop standards for multidisciplinary team approaches to providing TAVI.


“To ensure rational and responsible dissemination of this new technology, government, industry and medicine will need to work in harmony,” Holmes said in written comments submitted to the FDA before Wednesday’s hearing. “We look forward to this opportunity to work together to make high-quality patient care available to the appropriate patient population in the appropriate setting from appropriately experienced operators conducting the necessary followup.”


In his written comments, Holmes urged the panel to consider post-market research and surveillance, such as through a national database like the National Cardiovascular Data Registry (NCDR).


Currently, SCAI is leading the development of a multi-society policy statement on institutional and operator requirements to define the essential criteria for optimal patient outcomes with the ACC, STS and the American Association for Thoracic Surgery (AATS).  

Reference:
1. Leon, M.B., et al., “Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery.” New England Journal of Medicine. Oct. 21, 2010; 363(17):1597-607

Related Content

AtriCure, AtriClip PRO2 LAA Exclusion System, left atrial appendage, FDA clearance
Technology | Left Atrial Appendage (LAA) Occluders| April 29, 2016
April 29, 2016 — AtriCure Inc. announced U.S.
Feature | Business| April 28, 2016 | Dave Fornell
 
Mitralign Percutaneous Annuloplasty System, MPAS, CE Mark approval
News | Annuloplasty Rings| April 27, 2016
Mitralign Inc. announced its Mitralign Percutaneous Annuloplasty System (MPAS) has received CE mark approval from its...
TAVR, Sapien 3, ACC.16
Feature | Heart Valve Repair| April 19, 2016 | Michael J. Rinaldi, M.D., FACC, FSCAI
The continuation of positive clinical trial data for transcatheter aortic valve repair (TAVR), showing it is equal to
Sapien III, Sapien 3, PARTNER II

The Sapien 3 valve has a skirt that has helped significantly reduce paravalvular leaks, which were an issue with earlier generation Sapien devices. 

Feature | Heart Valve Repair| April 15, 2016
April 15, 2016 — Intermediate-risk patients who received transcatheter aortic valve replacement (TAVR) with the lates
TAVR runoff image

A 3-D CT reconstruction of a TAVR run-off image to assess the femoral access route using Toshiba's Aquillion One and Vital Images advanced visualization technologies. 

Feature | Heart Valve Repair| April 15, 2016
April 15, 2016 — Accurate and precise anatomical information is crucial to successful transcatheter aortic valve repl
TAVR, Sapien 3, ACC.16

Implantation of an Edwards Lifesciences Sapien valve under angiography during the balloon inflation to expand the valve into the aortic annulus. 

Feature | Heart Valve Repair| April 15, 2016
April 15, 2016 —The more frequently a hospital performs a transcatheter aortic valve replacement (TAVR) the better pa
Sponsored Content | Videos | Left Atrial Appendage (LAA) Occluders| April 15, 2016
David Holmes, M.D., professor of medicine, Mayo Clinic College of Medicine and consultant, Department of Internal Med
Sponsored Content | Videos | Heart Valve Repair| April 15, 2016
John Carroll, M.D., professor of medicine at the University of Colorado School of Medicine, and director of intervent
Sponsored Content | Videos | Heart Valve Repair| April 15, 2016
Chandan Devireddy, M.D., assistant professor of medicine at Emory Healthcare in Atlanta and an investigator in the PA
Overlay Init